BIO-KOREA
11.3.2024 14:02:25 CET | Business Wire | Press release
BIO KOREA 2024, jointly held by the Korea Health Industry Development Institute (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do (Governor: Kim Young-hwan), has commenced its registration for Business Partnering on March 4, 2024 (Mon.).
Business Partnering, one of the major programs at BIO KOREA, provides opportunities for one-on-one meetings between companies at home and abroad, alongside pertinent institutions within the BioHealth sector. This business matchmaking will foster discussions on potential business and research collaborations, encompassing collaborative research, market entry, and technology transfers.
In 2023, the easing of COVID-19 restrictions has led to increased participation. As many as 782 companies from 51 countries attended on-site events and 1,320 business meetings were arranged. This year, the Business Partnering Center will be expanded to provide more opportunities for participating companies to make business connections.
Throughout the three-day event from May 8 (Wed.) to May 10 (Fri.), the Business Partnering will unfold both online and offline on the sidelines of BIO KOREA 2024. In particular, online meetings will be supported round-the-clock to guarantee seamless engagements with international counterparts.
Companies seeking to engage in the Business Partnering should register through either the FCA or OPA options. Those pre-registering with the FCA by April 30 (Tue.), will receive a 10% discount.
* FCA (Full Convention Access): Grants in-person participation across all programs, including conferences, exhibitions, and Business Partnering, for the three-day event.
* OPA (Online Partnering Access): Provides access to online business partnering activities over the three-day event.
Meanwhile, due to an overwhelming response from domestic and overseas entities, applications for participation in the fair have closed earlier than anticipated.
This year, at least 50 foreign companies and research institutions are expected to be present with delegations from Business Sweden in Seoul, the Danish Embassy in Korea, Austrade, and Biocom California in the USA. Furthermore, a heightened presence of local enterprises from various countries, such as Germany, Thailand, and Taiwan, is expected to explore commercial prospects with Korean companies, given their participation in the national pavilion booths.
Participants include major domestic and foreign companies, including ST Pharm, Yuhan Corporation, Lonza, Wuxi Apptech, Fujifilm, and Labcorp. Exhibition booths for advanced regenerative medicine companies, including a Special Hall for AI featuring digital healthcare companies, will be opened as well.
More information is available on the BIO KOREA 2024 website (www.biokorea.org). Companies interested in Business Partnering can register via the website.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311710731/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ThetaRay Named World’s Best Software Provider for AML and Sanctions Screening in the 2026 Euromoney Transaction Banking Awards5.11.2026 19:30:00 CET | Press release
Recognition caps standout year alongside ThetaRay’s Top 10 (#8) ranking in the 2026 Chartis Financial Crime and Compliance50 (FCC50) and category win for Explainable AI. ThetaRay, a global leader in AI-native financial crime compliance infrastructure, has been named The World’s Best Software Provider for AML and Sanctions Screening at the 2026 Euromoney Transaction Banking Awards. Evaluated by Euromoney’s editorial and research team, ThetaRay was recognized for technology excellence, verifiable performance, and advancing the modern transaction banking value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105714764/en/ The recognition reinforces ThetaRay’s standing as foundational compliance infrastructure for global institutions, closely following Chartis Research ranking ThetaRay #8 globally in the Financial Crime and Compliance50 (FCC50) 2026 report and naming the company a Category Winner for Explainable AI. “Our
Arthur D. Little: H1 2026 Private Capital Fundraising Strengthens While Market Sentiment Highlights Investor Shift to Europe over US and Asia5.11.2026 18:58:00 CET | Press release
H1 fundraising up 6% year-on-year as 43% of LPs see geopolitical volatility favouring European funds AI usage dominates industry attention, defence leads target investment themes Invest Europe, the association representing Europe’s private equity, venture capital and infrastructure sectors, as well as their investors, today released ‘Investing in Europe: Private Equity Activity H1 2026’ and ‘The Insight: State of the European Private Equity Industry 2026’, an annual market sentiment report published jointly with global management consultancy Arthur D. Little (ADL). Together, these show increased fundraising for European private equity and venture capital versus the same period last year, stronger investor allocation expectations for Europe, and declining appetite for the US and Asia. The sentiment report also demonstrates how AI is reshaping the industry and portfolio companies, while defence-related themes are topping GPs’ target investments. GPs (General Partners/fund managers of PE
Angelalign Appoints Marco Gadola as Senior Advisor5.11.2026 18:35:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) http://www.angelaligner.com, a global clear aligner leader, today announced that Marco Gadola has joined Angel as Senior Advisor. In this role, Marco will advise the Board and senior management on culture, strategy and governance. Marco, who has held many leadership positions, is well-known as a former CEO of Straumann Group, a leading global medical device company focused on dentistry. Marco said he is excited to join Angel. “I’ve followed Angel for 10 years and have seen how it has evolved,” he said, “It’s grown from a regional leader in innovative clinical solutions and high-quality products, to a worldwide organization trusted by orthodontic specialists, with an impressive innovation pipeline.” Fox Hu, CEO of Angel, said: “Angel has strong core capabilities, but we must continue to improve to serve orthodontists even better. We welcome Marco as an advocate for our customers and employees around the world and to help us build an outstan
Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms5.11.2026 17:25:00 CET | Press release
Boomi governs agents, with flexibility across cloud, hybrid, and fully on-premises deployments behind the firewall. Boomi, the data activation company for AI, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. Boomi delivers agent management capabilities through the Agent Control Plane. Boomi believes this placement reflects its approach to solving one of the biggest hurdles in turning AI into ROI, by providing critical AI infrastructure that connects, governs, and controls AI costs across agents and skills from native and third-party providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105515847/en/ Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms Key Takeaways Boomi has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. A complimentary copy of t
Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products5.11.2026 16:04:00 CET | Press release
Biocodex, an independent French pharmaceutical company, announces a €15 million investment to develop an industrial platform in Beauvais, France, dedicated to Live Biotherapeutic Products (LBPs) derived from the microbiome. Building on more than 70 years of expertise in living microorganisms, microbiota, fermentation and pharmaceutical manufacturing, Biocodex aims to support its partners and, ultimately, its own programs, from research through to clinical and commercial production. The project aims to strengthen healthcare and industrial sovereignty in the field of next-generation microbiome-based therapies. Scientific advances in microbiome science are opening up new therapeutic perspectives, notably in oncology, inflammatory bowel diseases, certain rare diseases and women’s health. Moving from research to pharmaceutical production requires facilities adapted to living microorganisms and pharmaceutical requirements. Open to biotechnology companies worldwide, it will support LBP progra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom